Targeted dosing to treat pediatric inflammatory bowel disease is challenging because dosing guidelines are based on data gathered from adult subjects of clinical trials. Patients’ families and health care organizations also incur high costs and must try to balance potential benefits against risks of ongoing monitoring.
AMA J Ethics. 2018;20(9):E841-848. doi:
10.1001/amajethics.2018.841.
Drs Michael Young, Robert Regenhardt, and Leonard Sokol join Ethics Talk to discuss their article, coauthored with Dr Thabele Leslie-Mazwi: "When Should Neuroendovascular Care for Patients With Acute Stroke Be Palliative?"